Biopharmaceutical behemoth Gilead Sciences (GILD) has reported that new data from a phase 3 study (TROPiCS-02) evaluating Trodelvy against comparator chemotherapies indicate a progression-free survival (PFS) in breast cancer patients (irrespective of the status of their HER2 mutation). Further detailed results are expected on September 10 at the European Society for Medical Oncology (ESMO) Congress 2022. Bill Grossman, MD, Ph.D., Senior Vice president, Therapeutics Area Head, Gilead Oncology commented, “Trodelvy is already transforming the standard of care in second-line metastatic triple-negative breast cancer, and we are excited about its potential in other breast cancers where there is a significant need for new treatment options.
https://www.tipranks.com/news/article/how-is-gilead-nasdaqgild-stock-positioned-ahead-of-esmo-this-week?utm_source=advfn.com&utm_medium=referral